Finding reliable data to support clinical screening is a challenge

At a time when physicians and pharmacists are facing hundreds of medication-related decisions each day, the complexity of using EMRs and the rise of adverse drug events globally make it an ongoing challenge to deliver the best patient care. What’s more, a variety of factors about the patient must be taken into account before making medication decisions, or the consequences can be dire. We are here to help.

Medi-Span Clinical offers a variety of clinical screening modules
  • Dose Screening + Drug Orders
    • Provides information about a drug’s dose, frequency, and duration of therapy (Dose Screening), dosing at the ingredient level of a drug; and instructions for use—often referred to as sigs, the latin for “to write” (Drug Orders)*
    • Dose range screening for adult, pediatric, and neonatal patient populations
    • Patient inputs include patient age, weight, body surface area, renal function, medical condition, and dose type
    • Multiple types of screening can be performed including daily low/high/max, single dose max, frequency low/high/max, therapy duration low/high/max, and lifetime max

    * Drug Orders functionality is not available in all countries

  • Drug Allergy Screening
    • Provides data content about drug allergies and associated adverse reactions
    • Includes drugs and herbal/natural products
    • Facilitates screening by ingredient, allergen class, or drug product
    • Differentiates allergies by type; same drug, same class, or cross-sensitivity
    • Additionally, the API provides “common” concepts for allergens that facilitate creation of a clinician picklist that can be used to populate a patient’s allergy profile
  • Drug Disease Contraindications
    • Assists in the detection and reporting of conflicts related to the use of a medication in a patient with a given disease state or known genetic factors
    • Filter parameter available for Severity Level filtering; parameter ranges from Contraindicated to Informational levels
  • Drug Interaction Screening
    • Provides information about drug-drug, drug-food, and drug-alcohol interactions
    • Provides route and ingredient-specific interactions and allows for latency interactions
    • Includes attributes for severity, includes level of supporting documentation, management, and onset
    • Considers contextual factors such as age, gender, and dosage when providing information on interactions
  • Duplicate Therapy Screening
    • Provides data to support screening for potentially inappropriate therapeutic duplications. Includes codes identifying duplications involving ingredient, mechanism of action, or therapeutic indication, as well as a Duplication Allowance Indicator to specify a number of acceptable duplications before providing an alert
  • Pregnancy, Lactation, Age, and Gender Screening
    • Provides data to support screening for potential therapeutic conflicts between a drug and a patient based on available information about current medical condition, age, gender, pregnancy/lactation status, and known pharmacogenomic factors
    • The significance of the therapeutic conflict is quantified, allowing users to determine which screening alerts they wish to receive
  • Route Contraindications
    • Identifies routes of administration contraindicated or not recommended due to:
      • Safety concerns (e.g., Vincristine Sulfate via intrathecal route, otic solutions via ophthalmic route)
      • Drug formulation (e.g., extended release oral tablets via nasogastric tube)
  • US Controlled Substances
    • For the US only, displays a drugs’ Drug Enforcement Agency (DEA), State or Territory schedule status (when available)
    • For the US only, denotes if a National Drug Code (NDC) is required for an electronic prescription (if available)
Back To Top